Recombinant Mouse CXCL9/MIG Protein

• Reactivity: Mu
• Applications: Bioactivity

Recombinant Mouse CXCL9/MIG Protein Summary

• Details of Functionality: Measured by its ability to chemoattract human peripheral blood lymphocytes (PBL) cultured in the presence of IL-2 for 21 days. The ED₅₀ for this effect is 0.1‑0.3 µg/mL. Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with mouse CXCR3. The ED₅₀ for this effect is 0.1 - 0.5 µg/mL.
• Source: E. coli-derived mouse CXCL9/MIG protein
  Thr22-Thr126
• Accession #: P18340
• N-terminal Sequence: Thr22
• Protein/Peptide Type: Recombinant Proteins
• Gene: Cxcl9
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 12 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse CXCL9/MIG Protein

• chemokine (C-X-C motif) ligand 9
• CMK
• crg-10
• C-X-C motif chemokine 9
• CXCL9
• Gamma-interferon-induced monokine
• Humig
• MIG
• MIGSmall-inducible cytokine B9
• monokine induced by gamma interferon
• SCYB9Monokine induced by interferon-gamma

Background

CXCL9, also known as MIG, is a member of the alpha  subfamily of chemokines that lacks the ELR domain, and was initially identified as a lymphokine-activated gene in mouse macrophages. Human CXCL9 was subsequently cloned using mouse CXCL9 cDNA as a probe. The CXCL9 gene is induced in macrophages and in primary glial cells of the central nervous system specifically in response to IFN-gamma . CXCL9 has been shown to be a chemoattractant for activated T-lymphocytes and TIL but not for neutrophils or monocytes. The mouse CXCL9 cDNA encodes a 126 amino acid residue precursor protein with a 21 amino acid residue signal peptide that is cleaved to yield a 105 amino acid residue mature protein. CXCL9 has an extended carboxy-terminus containing greater than 50% basic amino acid residues and is larger than most other chemokines. The carboxy-terminal residues of CXCL9 are prone to proteolytic cleavage resulting in size heterogeneity of natural and recombinant CXCL9. CXCL9 with large carboxy-terminal deletions have been shown to have diminished activity in the calcium flux assay. A chemokine receptor (CXCR3) specific for CXCL9 and IP-10 has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes. The E. coli-expressed CXCL9 produced at R&D Systems has been shown to contain greater than 80% full length CXCL9.

1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
2. Liao, F. et al. (1995) J. Exp. Med. 182:1301.
3. Vanguri, P. (1995) J. Neuroimmunol. 56:35.

Publications for CXCL9/MIG (492-MM)(11)

Publications using 492-MM

• Koya, J;Tanigawa, T;Mizuno, K;Kim, H;Ito, Y;Yuasa, M;Yamaguchi, K;Kogure, Y;Saito, Y;Shingaki, S;Tabata, M;Murakami, K;Chiba, K;Okada, A;Shiraishi, Y;Marouf, A;Liévin, R;Chaubard, S;Jaccard, A;Hermine, O;de Leval, L;Tournilhac, O;Damaj, G;Gaulard, P;Couronné, L;Yasui, T;Nakashima, K;Miyoshi, H;Ohshima, K;Kataoka, K; Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets Nature communications 2024-10-22 [PMID: 39438472] (Bioassay, Transgenic Mouse)
• M Hashimoto, K Araki, MA Cardenas, P Li, RR Jadhav, HT Kissick, WH Hudson, DJ McGuire, RC Obeng, A Wieland, J Lee, DT McManus, JL Ross, SJ Im, J Lee, JX Lin, B Hu, EE West, CD Scharer, GJ Freeman, AH Sharpe, SS Ramalingam, A Pellerin, V Teichgräbe, WJ Greenleaf, C Klein, JJ Goronzy, P Umaña, WJ Leonard, KA Smith, R Ahmed PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program Nature, 2022-09-28;610(7930):173-181. 2022-09-28 [PMID: 36171288] (Bioassay, Mouse)
• T Hasegawa, V Venkata Su, Y Yahata, M Nakano, S Suzuki, S Suzuki, S Yamada, H Kitaura, I Mizoguchi, Y Noiri, K Handa, M Saito Inhibition of the CXCL9-CXCR3 axis suppresses the progression of experimental apical periodontitis by blocking macrophage migration and activation Scientific Reports, 2021-01-28;11(1):2613. 2021-01-28 [PMID: 33510341] (Bioassay, Mouse)
• T Yano, M Ohira, R Nakano, Y Tanaka, H Ohdan Hepatectomy leads to loss of TRAIL-expressing liver NK cells via downregulation of the CXCL9-CXCR3 axis in mice PLoS ONE, 2017-10-31;12(10):e0186997. 2017-10-31 [PMID: 29088306] (Bioassay, Mouse)
• ERO Allan, RI Campden, BW Ewanchuk, P Tailor, DR Balce, NT McKenna, CJ Greene, AL Warren, T Reinheckel, RM Yates A role for cathepsin Z in neuroinflammation provides mechanistic support for an epigenetic risk factor in multiple sclerosis J Neuroinflammation, 2017-05-10;14(1):103. 2017-05-10 [PMID: 28486971] (Bioassay, Mouse)
• P Shinde, W Liu, A Ménoret, AD Luster, AT Vella Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production J. Leukoc. Biol., 2017-04-21;0(0):. 2017-04-21 [PMID: 28432083] (Western Blot, Mouse)
• Murine liver-resident group 1 innate lymphoid cells regulate optimal priming of anti-viral CD8+ T cells J Leukoc Biol, 2016-08-04;0(0):. 2016-08-04 [PMID: 27493244] (Bioassay, Mouse)
• Zychowska M, Rojewska E, Pilat D, Mika J The role of some chemokines from the CXC subfamily in a mouse model of diabetic neuropathy. J Diabetes Res, 2015-02-19;2015(0):750182. 2015-02-19 [PMID: 25789329] (Mouse)
• Krauthausen M, Kummer M, Zimmermann J, Reyes-Irisarri E, Terwel D, Bulic B, Heneka M, Muller M CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer&#039;s disease model. J Clin Invest, 2014-12-15;125(1):365-78. 2014-12-15 [PMID: 25500888] (Bioassay, Mouse)
• Lacotte S, Decossas M, Le Coz C, Brun S, Muller S, Dumortier H Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS ONE, 2013-03-08;8(3):e58140. 2013-03-08 [PMID: 23520491] (Bioassay, Mouse)
• Liu C, Luo D, Reynolds BA Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis, 2010-11-03;32(2):129-37. 2010-11-03 [PMID: 21051441] (Bioassay, Mouse)

Bioinformatics

• Gene Symbol: Cxcl9
• Uniprot:
  • P18340()